Teva Pharmaceutical Industries Limited (TEVA) Announces AZILECT® (Rasagiline Tablets) Data to be Presented at the 2013 International Congress of Parkinson’s Disease and Movement Disorders
6/14/2013 7:06:21 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson’s Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society (MDS). These presentations affirm Teva’s ongoing commitment to Parkinson’s disease (PD) research and underscore the potential of AZILECT® as a treatment modality for PD.
Help employers find you! Check out all the jobs and post your resume.
comments powered by